Is Aayush Wellness overvalued or undervalued?

As of 23 September 2025, Aayush Wellness has moved from an expensive to a very expensive valuation grade. The company is currently overvalued, with a PE ratio of 80.47, a Price to Book Value of 41.50, and an EV to EBITDA ratio of 94.82. These figures significantly exceed those of its peers, such as Sun Pharma, which has a PE ratio of 34.11, and Divi's Lab, with a PE of 69.64, indicating that Aayush Wellness is trading at a premium compared to the industry. The company's high valuation is further underscored by its PEG ratio of 0.08, suggesting that despite a high price relative to earnings, growth expectations may not justify such a valuation. Additionally, while Aayush Wellness has shown impressive returns over the long term, including a staggering 4993.07% return over three years, its recent performance has been lackluster, with a year-to-date decline of 43.51% compared to a 5.07% gain in the Sensex. This disparity reinforces the notion that the stock is overvalued in the current market context.